Revelyx Bio Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Revelyx Bio Inc. - overview
Established
2025
Location
Delaware, OH, US
Primary Industry
Biotechnology
About
Founded in 2025 and based in Ohio, US, Revelyx Bio Inc. operates as a biotech company developing liquid botulinum toxin products for cosmetic and medical use. In January 2026, Revelyx Bio Inc. raised series A funding led by NRL Capital.
Revelyx Bio specializing in next‑generation botulinum toxin therapies designed for aesthetic and medical applications. The firm develops botulinum toxin type A liquid formulation (pipeline: 003) engineered for higher efficacy, lower immunogenicity, improved resistance profiles, and greater precision, offering a more user‑friendly alternative to traditional toxin products. The company plans to use the series A funding to promote clinical research and development and expand its products globally.
Current Investors
NRL Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.